STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Alkermes to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Alkermes (Nasdaq: ALKS) said management will participate in two investor conferences in November 2025: the Stifel 2025 Healthcare Conference on Nov. 13, 2025 at 2:40 p.m. ET and the Jefferies Global Healthcare Conference in London on Nov. 19, 2025 at 11:30 a.m. ET.

Both events will be webcast live and the webcasts will be available under the Investors tab at www.alkermes.com and archived for 14 days.

Alkermes (Nasdaq: ALKS) ha dichiarato che la direzione parteciperà a due conferenze per investitori nel novembre 2025: la Stifel 2025 Healthcare Conference il 13 novembre 2025 alle 14:40 ET e la Jefferies Global Healthcare Conference a Londra il 19 novembre 2025 alle 11:30 ET. Entrambi gli eventi saranno trasmessi in diretta e le webcast saranno disponibili nella scheda Investitori su www.alkermes.com e archiviate per 14 giorni.

Alkermes (Nasdaq: ALKS) dijo que la dirección participará en dos conferencias para inversionistas en noviembre de 2025: la Conferencia de Salud 2025 de Stifel el 13 de noviembre de 2025 a las 2:40 p.m. hora del Este y la Conferencia Global de Salud de Jefferies en Londres el 19 de noviembre de 2025 a las 11:30 a.m. hora del Este.

Ambos eventos se transmitirán en vivo y las transmisiones estarán disponibles bajo la pestaña de Inversionistas en www.alkermes.com y quedarán archivadas durante 14 días.

Alkermes (나스닥: ALKS)는 2025년 11월 두 차례의 투자자 회의에 경영진이 참여할 것이라고 밝혔습니다: Stifel 2025 Healthcare Conference2025년 11월 13일 동부표준시 14:40에, Jefferies Global Healthcare Conference in London2025년 11월 19일 동부표준시 11:30에 열립니다. 두 행사 모두 생중계되며, 생방송은 www.alkermes.com의 투자자 탭에서 확인 가능하고 14일간 보관됩니다.

Alkermes (Nasdaq: ALKS) a déclaré que la direction participera à deux conférences pour investisseurs en novembre 2025 : la Stifel 2025 Healthcare Conference le 13 novembre 2025 à 14 h 40, heure de l'Est et la Jefferies Global Healthcare Conference à Londres le 19 novembre 2025 à 11 h 30, heure de l'Est.

Les deux événements seront diffusés en direct et les webcasts seront disponibles dans l’onglet Investisseurs sur www.alkermes.com et archivés pendant 14 jours.

Alkermes (Nasdaq: ALKS) sagte, dass das Management an zwei Investorenkonferenzen im November 2025 teilnehmen wird: die Stifel 2025 Healthcare Conference am 13. November 2025 um 14:40 Uhr EST und die Jefferies Global Healthcare Conference in London am 19. November 2025 um 11:30 Uhr EST. Beide Veranstaltungen werden live gestreamt, und die Webcasts sind unter dem Reiter "Investoren" auf www.alkermes.com verfügbar und für 14 Tage archiviert.

Alkermes (ناسداك: ALKS) قالت أن الإدارة ستشارك في مؤتمرين للمستثمرين في نوفمبر 2025: مؤتمر ستيفل للرعاية الصحية 2025 في 13 نوفمبر 2025 الساعة 2:40 مساءً بتوقيت شرق الولايات المتحدة ومؤتمر Jefferies العالمي للرعاية الصحية في لندن في 19 نوفمبر 2025 الساعة 11:30 صباحاً بتوقيت شرق الولايات المتحدة. سيُبَث الحدثان مباشرةً وستكون البثوث متاحة ضمن علامة التبويب المستثمرين على www.alkermes.com ومؤرشَفة لمدة 14 يوماً.

Positive
  • None.
Negative
  • None.

DUBLIN, Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.

Stifel 2025 Healthcare Conference
Date/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT)

Jefferies Global Healthcare Conference in London
Date/Time: Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302607396.html

SOURCE Alkermes plc

FAQ

When will Alkermes (ALKS) present at the Stifel 2025 Healthcare Conference?

Alkermes will present on Nov. 13, 2025 at 2:40 p.m. ET.

What time is Alkermes (ALKS) scheduled for the Jefferies Global Healthcare Conference in London?

The Alkermes presentation is scheduled for Nov. 19, 2025 at 11:30 a.m. ET.

How can investors watch Alkermes (ALKS) webcasts for the November 2025 conferences?

Live webcasts are available under the Investors tab at www.alkermes.com.

How long will Alkermes (ALKS) conference webcasts be archived after the live events?

The webcasts will be archived and available for 14 days after the live event.

Will Alkermes (ALKS) provide on-demand access for both November 2025 conference presentations?

Yes; both presentations will be webcast live and archived for on-demand access for 14 days.

Where is Alkermes (ALKS) headquartered and what areas does its portfolio target?

Alkermes is headquartered in Ireland and has products and a pipeline focused on neuroscience disorders including treatment areas such as alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, narcolepsy, and idiopathic hypersomnia.
Alkermes Plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Latest SEC Filings

ALKS Stock Data

5.39B
161.39M
1.49%
104.97%
8.06%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 4